Abstract: Cancer treatment methods using thermotherapy and/or enhanced immunotherapy are disclosed herein. One two-stage cancer treatment method comprises the steps of: (i) in a first stage, administering, to a patient with a metastatic malignancy, tumor-antibody-coated nanoparticles conjugated with one or more medications and/or one or more immune stimulators for attaching to circulating exosomes, extracellular vesicles, and/or circulating tumor cells, thus promoting a destruction of the circulating exosomes, extracellular vesicles, and/or circulating tumor cells by a cellular immune system of the patient; and (ii) in a second stage, treating a main tumor of the patient during the same session or during another session of therapy by administering the tumor-antibody-coated nanoparticles conjugated with the one or more medications and/or the one or more immune stimulators so as to stimulate the cellular immune response of the patient to destroy the main tumor.

Abstract: A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) forming a flap in a cornea of an eye so as to expose a stromal tissue of the cornea underlying the flap; (ii) pivoting the flap so as to expose the stromal tissue of the cornea underlying the flap; (iii) inserting an implant under the flap so as to overlie the stromal tissue of the cornea; (iv) applying laser energy and/or microwaves to the implant in the eye so as to modify the refractive power of the implant; (v) applying a cross-linking solution that includes a photosensitizer to the implant; (vi) covering the implant with the flap; and (vii) irradiating the implant so as to activate cross-linkers in the implant, and thereby cross-link the implant and the stromal tissue of the cornea surrounding the implant.

Abstract: A method of treatment is disclosed herein. The method includes administering to a patient in need thereof a polymer implant device containing a biocompatible drug, or a plurality of nanoparticles or microparticles conjugated with the biocompatible drug, the biocompatible drug comprising one or more Rock inhibitors, one or more Wnt inhibitors, one or more integrin inhibitors, and/or one or more glycogen synthase kinase 3 (GSK-3) inhibitors, the patient having a medical condition selected from the group consisting of dry eye, glaucoma, retinal detachment, retinal degeneration, age-related macular degeneration, a cataract, uveitis, a corneal genetic disease, postoperative inflammation, immune-related inflammatory processes, diabetic retinopathy, a side effect occurring after cataract surgery, a side effect occurring after refractive surgery, and combinations thereof.

Abstract: A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) prior to implantation, treating an implant formed from donor corneal tissue or a tissue culture grown corneal stroma with a solution of sodium dodecyl sulfate (SDS), Triton X-100, benzalkonium chloride (BAK), Igepal, genipin, 100% glycerol, or alcohol for making the implant acellular, and for killing any bacteria, viruses, or parasites prior to implantation; (ii) implanting the implant into a recipient cornea; (iii) applying laser energy to the implant so as to modify the refractive power of the implant while being monitored using a Shack-Hartmann wavefront system so as to achieve a desired refractive power for the implant; and (iv) applying a cross-linking solution and irradiating the implant to cross-link the implant to prevent an immune response to the implant and/or rejection of the implant by a patient.

Abstract: A method of forming and implanting a synthetic corneal lenslet in an eye of a patient includes the steps of: forming a synthetic lenslet from a collagen solution using a mold or a 3-D printer that are configured to form the synthetic lenslet into a predetermined shape for correcting a particular refractive error of the patient; forming a cavity for receiving the synthetic lenslet in the cornea of the eye of the patient; inserting the synthetic lenslet into the cavity of the eye; applying a photosensitizer into the cavity of the eye so that the photosensitizer permeates at least a portion of the tissue surrounding the cavity and at least a portion of the synthetic lenslet; and irradiating the cornea so as to activate cross-linkers in the synthetic lenslet and cross-linkers in the portion of the tissue surrounding the cavity, and thereby prevent an immune response.

Abstract: A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.

Abstract: A glaucoma testing device and a method of using the same are disclosed herein. The glaucoma testing device includes a device body portion having an outer housing and a flexible membrane at least partially defining a chamber supported within the outer housing; a fluid control system configured to insert an amount of the fluid into the chamber of the device body portion in order to expand the flexible membrane and exert pressure on an eye of a patient, or remove an amount of the fluid from the chamber of the device body portion in order to deflate the membrane and relieve pressure exerted on the eye; and a laser fiber optic configured to transmit a beam of light into the eye so as to produce a detectable ultrasonic wave so that an oxygenation level of the eye of the patient is capable of being determined using a photoacoustic system.

Abstract: A method of therapy for a tumor or other pathology by administering thermotherapy or a combination of thermotherapy and immunotherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and prevents tumor recurrence, either locally or at a different site, by boosting the patient's immune response both at the time of original therapy and/or for later therapy. The therapy may further include the administration of a vaccine.

Abstract: An apparatus (200, 200A, 200B, 200C) has central lens body (212, 212A, 212B, 212C) for providing vision correction for a patient. The lens body (212, 212A, 212B, 212C) has an initial index of refraction and is formed from at least one material configured to have a second index of refraction when subjected to a laser and/or radiation.

Abstract: A method of intracorneal lens implantation with a cross-linked cornea is disclosed herein. The method includes forming a pocket in a cornea of an eye, applying a photosensitizer inside the pocket so that the photosensitizer permeates at least a portion of the tissue bounding the pocket, the photosensitizer facilitating cross-linking of the tissue bounding the pocket; irradiating the cornea so as to activate cross-linkers in the portion of the tissue bounding the pocket, and thereby kill cells therein; inserting a lens implant into the pocket; and applying laser energy to the lens implant in the pocket using a laser so as to correct refractive errors of the lens implant and/or the eye in a non-invasive manner. In other embodiments, a lens implant is soaked in a cross-linking solution that includes a photosensitizer prior to being inserted into the pocket in the cornea of an eye.

Abstract: A system for preventing motion sickness resulting from virtual reality or augmented reality is disclosed herein. In one embodiment, the system includes a virtual reality or augmented reality headset configured to be worn by a user, the virtual reality or augmented reality headset configured to create an artificial environment and/or immersive environment for the user; at least one fluidic lens disposed between an eye of the user and a screen of the virtual reality or augmented reality headset; and a fluid control system operatively coupled to the at least one fluidic lens. In another embodiment, the system includes at least one tunable prism disposed between an eye of the user and a screen of the virtual reality or augmented reality headset, the at least one tunable prism configured to correct a convergence problem associated with the eye of the user.

Abstract: An intraocular lens has central lens body at least one haptic extending from the central lens body. The haptic has a lobular configuration. The lens body and the haptic having a folded configuration for implantation within the eye. The lens having a first deployed configuration wherein the lens body is positioned at a location substantially behind sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over top of the sealed anterior and posterior portions of the lens capsule. The lens having a second deployed configuration wherein the lens body is positioned at a location substantially in front of the sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over behind the sealed anterior and posterior portions of the lens capsule.

Abstract: A method of corneal and scleral inlay crosslinking and preservation is disclosed herein. The method includes cross-linking at least a portion of a donor cornea or a donor sclera so as to kill cellular elements in the portion of the donor cornea or the donor sclera, and make the portion of the donor cornea or the donor sclera less antigenic to a body portion of a recipient patient in which the portion of the donor cornea or the donor sclera is to be implanted; and storing the cross-linked donor cornea or the donor sclera for a long period of time prior to implanting the portion of the donor cornea or the donor sclera into the body portion of the recipient patient.

Abstract: A fluidic light field camera is disclosed herein. The fluidic light field camera includes a fluidic objective lens; a fluid control system operatively coupled to the fluidic objective lens, the fluid control system to change the shape* of the fluidic objective lens in accordance with the amount of fluid therein; a microlens array disposed behind the fluidic objective lens: a sensor array disposed behind the microlens array; and a data processing device operatively coupled to the fluid control system and the sensor array, the data processing device configured to vary the focal point of the fluidic light field camera by using the fluid control system to control the shape of the fluidic objective lens, thereby enabling all portions of an image being captured by the fluidic light field camera to be in focus during a single recording cycle of the fluidic light field camera.

Abstract: A fluidic light field camera is disclosed herein. The fluidic light field camera includes a fluidic objective lens; a fluid control system operatively coupled to the fluidic objective lens, the fluid control system to change the shape of the fluidic objective lens in accordance with the amount of fluid therein; a microlens array disposed behind the fluidic objective lens; a sensor array disposed behind the microlens array; and a data processing device operatively coupled to the fluid control system and the sensor array, the data processing device configured to vary the focal point of the fluidic light field camera by using the fluid control system to control the shape of the fluidic objective lens, thereby enabling all portions of an image being captured by the fluidic light field camera to be in focus during a single recording cycle of the fluidic light field camera.

Abstract: An intraocular lens has central lens body at least one haptic extending from the central lens body. The haptic has a lobular configuration. The lens body and the haptic having a folded configuration for implantation within the eye. The lens having a first deployed configuration wherein the lens body is positioned at a location substantially behind sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over top of the sealed anterior and posterior portions of the lens capsule. The lens having a second deployed configuration wherein the lens body is positioned at a location substantially in front of the sealed anterior and posterior portions of the lens capsule with the at least one haptic positioned at a location substantially over behind the sealed anterior and posterior portions of the lens capsule.

Abstract: A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) cutting a circular implant from a donor cornea; (ii) cutting the circular implant into a plurality of constituent pieces; (iii) forming a small incision in a recipient cornea of an eye of a patient; (iv) forming a pocket in the recipient cornea of the eye of the patient, the pocket being accessible through the small incision in the recipient cornea, and the pocket being bounded entirely by stromal tissue of the cornea; and (v) inserting each of the plurality of constituent pieces of the implant into the pocket of the recipient cornea via the small incision, wherein the implant is cross-linked so as to prevent an immune response to the implant and/or rejection of the implant by the patient.

Abstract: A telemedicine system with dynamic imaging is disclosed herein. In some embodiments, the telemedicine system comprises a laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with a laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. Also, in some embodiments, communication between the laser imaging and treatment apparatus and control system is achieved via the Internet®. Further, in some embodiments, the telemedicine system includes a dynamic imaging system and/or a facial recognition system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process.

Abstract: An integral laser imaging and treatment apparatus, and associated systems and methods that allow a physician (e.g., a surgeon) to perform laser surgical procedures on an eye structure or a body surface with an integral laser imaging and treatment apparatus disposed at a first (i.e. local) location from a control system disposed at a second (i.e. remote) location, e.g., a physician's office. In some embodiments, communication between the integral laser imaging and treatment apparatus and control system is achieved via the Internet®. Also, in some embodiments, the laser imaging and treatment apparatus includes a dynamic imaging system that verifies the identity of a patient, and is capable of being used for other important applications, such as tracking and analyzing trends in a disease process. Further, in some embodiments, the laser imaging and treatment apparatus determines the geographical location of the local laser generation unit of the system using GPS.

Abstract: A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) forming a flap in a cornea of an eye so as to expose a stromal tissue of the cornea underlying the flap; (ii) pivoting the flap so as to expose the stromal tissue of the cornea underlying the flap; (iii) inserting an implant under the flap so as to overlie the stromal tissue of the cornea; (iv) applying laser energy and/or microwaves to the implant in the eye so as to modify the refractive power of the implant; (v) applying a cross-linking solution that includes a photosensitizer to the implant; (vi) covering the implant with the flap; and (vii) irradiating the implant so as to activate cross-linkers in the implant, and thereby cross-link the implant and the stromal tissue of the cornea surrounding the implant.